玉林品牌怎么样 申请店铺

我要投票 玉林在中草药行业中的票数:72 更新时间:2025-02-05
玉林是哪个国家的品牌?「玉林」是 广西玉林制药集团有限责任公司 旗下著名品牌。该品牌发源于广西,由创始人高海恩在1985-11-28期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
玉林怎么样

广西玉林制药集团有限责任公司(原广西玉林制药厂)成立于1956年,2001年底由国有企业改制成有限责任公司,2011年5月变更为广西玉林制药集团有限责任公司。公司现有员工628人,其中中专以上学历各类专业技术人员159人,约占员工总数的25.3%,从事药品生产管理、质量管理的专业技术人员112人,其中高级工程师17人,工程师41人,助理工程师44人,技术员9人,执业药师38人。

集团公司下辖药用胶囊公司、天绿安公司、宏升贸易公司、玉铭中药材公司、玉药广告公司5个子公司。资产约3亿元,年产值约5亿元。公司生产设备精良,主要设备近千台(套),其中国外引进的先进设备50台(套),成为国内同行业中引进技术和设备最早、最多的企业之一。公司地址位于广西玉林市城站路1号,占地244349.4平方米,其中老厂区占地面积110949.平方米,仁厚新生产基地133400平方米。

公司总建筑面积约103000平方米,其中生产用建筑面积55000平方米,仓储面积28000平方米,绿化面积122466.2平方米,绿化面积占厂区面积的30%以上。公司的生产环境整洁优美,厂区分为生产区、辅助生产区、仓储区和办公区,布局合理。厂区道路全部硬化,不起尘,地面、路面及运输等均不对药品生产造成污染。

公司的机构设置主要分为三大块,一是营销中心下设销售部、市场部、督察部、供应部、仓库等;二是技术中心,下设质量部和科研部;三是生产运行中心,下设中药饮片车间、综合提取车间、固体制剂车间、酊水车间,中试车间,设备部等。

公司以中成药生产为主,现有胶囊剂、酊剂等九个剂型70多个品种。并于2003年元月顺利通过了国家药品GMP认证。认证范围包括胶囊剂、片剂、颗粒剂、糖浆剂和酊剂(含外用)五个剂型以及中药提取;2005年6月通过软膏剂、煎膏剂、合剂、搽剂四个剂型的GMP认证检查;此外,在1996~2010年间连续六次通过澳大利亚TGA的GMP认证及复查,为公司产品进一步拓展海外市场打下基础。我公司的生产范围于2004年9月增加了中药饮片,2007年月10月广西区食品药品监督管理局认证中心检查组对我公司进行了药品GMP认证复查,获得了通过。2004年以来,公司又投资1800多万元扩建中药材仓库、酒精仓库、改建配电房、改造中药饮片车间和固体制剂的造粒干燥工序操作间、中试车间及部分新设备的添置和质检精密仪器(高效液相)的添置,进一步改善了药品生产条件和环境,确保我公司生产的药品是在符合GMP要求的状态下进行。在软件方面对以往生产过程中使用的1000多份生产管理和质量管理文件以及相应记录进行了几次修订完善和提高。并多次进行了GMP知识的全员培训,公司的生产和质量管理均按GMP的规范进行。目前生产的剂型仍主要有酊剂、胶囊剂、颗粒剂、片剂、糖浆剂、软膏剂、煎膏剂、合剂、搽剂以及中药饮片等。我们每年定期对公司实施GMP工作情况开展自检,并形成了自检整改报告。通过自检整改,保证公司的药品生产和质量管理软件、硬件条件与GMP规范始终保持一致。

公司的主导品种正骨水收载在《中国药典》2000年版、2005年版和2010年版,鸡骨草胶囊、湿毒清胶囊、云香精、珍黄丸、睡安胶囊、乌军治胆片、草香胃康胶囊、银蒲解毒片等也收载于《中国药典》2010年版。并在国内外均享有较高声誉。还有30多个品种列入国家非处方药目录和医保目录。产品结构合理,疗效可靠,市场潜力巨大。公司是全国五十强中药生产企业之一,广西的两家中华老字号企业之一、广西百强工业企业之一,广西经济效益先进企业。2006年被国家商务部授予“中华老字号”称号;2007年“玉林牌”商标被评为中国驰名商标;从1988年起被国家授予自营进出口权,公司在全国以及东南亚国家和港、澳、台地区均有一定的知名度。

公司以“质量、市场、成本、效益”为办厂方针,始终将产品质量放在第一位,并将实施药品GMP作为一个新的起点,全面提高员工的质量意识和业务技术素质,提高企业管理水平,为人民的医药健康事业发展作出更大的贡献。

Guangxi Yulin Pharmaceutical Group Co., Ltd. (formerly Guangxi Yulin pharmaceutical factory) was established in 1956. At the end of 2001, it was transformed from a state-owned enterprise into a limited liability company, and changed into Guangxi Yulin Pharmaceutical Group Co., Ltd. in May 2011. At present, the company has 628 employees, including 159 professional and technical personnel with technical secondary school degree or above, accounting for 25.3% of the total number of employees. There are 112 professional and technical personnel engaged in drug production management and quality management, including 17 senior engineers, 41 engineers, 44 assistant engineers, 9 technicians and 38 licensed pharmacists. Under the jurisdiction of the group company, there are five subsidiaries: pharmaceutical capsule company, tianlu'an company, Hongsheng trading company, Yuming traditional Chinese medicine company and Yuyao advertising company. The assets are about 300 million yuan and the annual output value is about 500 million yuan. The company has excellent production equipment, with nearly 1000 sets of main equipment, including 50 sets of advanced equipment imported from abroad, becoming one of the earliest and most introduced enterprises in the same industry in China. The company is located at No.1 Chengzhan Road, Yulin City, Guangxi Province, covering an area of 244349.4 square meters, including 110949. Square meters of the old plant area and 133400 square meters of Renhou new production base. The total building area of the company is about 103000 square meters, including 55000 square meters of production building area, 28000 square meters of storage area, 122466.2 square meters of green area, accounting for more than 30% of the plant area. The production environment of the company is clean and beautiful. The plant area is divided into production area, auxiliary production area, storage area and office area, with reasonable layout. All roads in the plant area are hardened and free from dust. The ground, road surface and transportation will not cause pollution to drug production. The organization of the company is mainly divided into three parts: first, the marketing center consists of sales department, marketing department, supervision department, supply department, warehouse, etc.; second, the technology center consists of quality department and scientific research department; third, the production and operation center consists of herbal medicine decoction workshop, comprehensive extraction workshop, solid preparation workshop, tincture water workshop, pilot plant, equipment department, etc. The company is mainly engaged in the production of Chinese patent medicine, with more than 70 varieties of nine dosage forms including capsule and tincture. In January 2003, it successfully passed the national GMP certification. The certification scope includes five dosage forms of capsule, tablet, granule, syrup and tincture (including external use) as well as extraction of traditional Chinese medicine; in June 2005, it passed the GMP certification inspection of four dosage forms of ointment, decoction, mixture and liniment; in addition, it passed the GMP certification and review of TGA in Australia for six times in 1996-2010, laying a foundation for the company to further expand its overseas market. In September 2004, the production scope of our company increased pieces of Chinese herbal medicine. In October 2007, the inspection team of the certification center of Guangxi food and Drug Administration reviewed the GMP certification of our company and obtained the approval. Since 2004, the company has invested more than 18 million yuan to expand the warehouse of traditional Chinese medicine, the warehouse of alcohol, the transformation of power distribution room, the transformation of traditional Chinese medicine workshop and the operation room of granulation and drying process of solid preparation, the addition of pilot plant and some new equipment, and the addition of quality inspection precision instruments (high-performance liquid phase), further improving the pharmaceutical production conditions and environment, Ensure that the drugs produced by our company are in compliance with GMP requirements. In terms of software, more than 1000 production management and quality management documents and corresponding records used in the previous production process have been revised, improved and improved several times. And has carried on the GMP knowledge many times the entire staff training, the company's production and the quality management all carried on according to the GMP standard. At present, the main dosage forms are tinctures, capsules, granules, tablets, syrups, ointments, decoctions, mixtures, liniments and pieces of Chinese medicine. We conduct self inspection on GMP implementation of the company on a regular basis every year, and form self inspection rectification report. Through self inspection and rectification, ensure that the company's pharmaceutical production and quality management software and hardware conditions are consistent with GMP specifications all the time. The leading bone of the company is bone water collected in China Pharmacopoeia 2000, 2005 and 2010. Chicken bone grass capsule, wet poison capsule, Yun Xiang Jing, Zhen Huang pill, sleep pill, Wu Jun Zhi Dan tablet, Cao Xiang Wei Kang capsule, Yin Pu detoxification tablet are also collected in the 2010 edition of China Pharmacopoeia. And enjoy a high reputation at home and abroad. There are more than 30 varieties listed in the national over-the-counter drug catalog and medical insurance catalog. The product structure is reasonable, the curative effect is reliable and the market potential is huge. The company is one of the top 50 traditional Chinese medicine production enterprises in China, one of the two time-honored Chinese enterprises in Guangxi, one of the top 100 industrial enterprises in Guangxi, and an advanced enterprise with economic benefits in Guangxi. In 2006, it was awarded the title of "China Time-honored Brand" by the Ministry of Commerce of the people's Republic of China; in 2007, it was awarded the title of "Yulin brand" as a well-known trademark in China; since 1988, it has been granted the right of self import and export by the state, and the company has a certain reputation in the whole country and Southeast Asian countries, Hong Kong, Macao and Taiwan. The company takes "quality, market, cost and benefit" as the policy of running the factory, always puts product quality first, and takes the implementation of GMP as a new starting point, comprehensively improves the quality awareness and professional and technical quality of employees, improves the management level of the enterprise, and makes greater contribution to the development of the people's medical and health undertakings.

本文链接: https://brand.waitui.com/a6ebebba2.html 联系电话:07753892003

千城特选小程序码

7×24h 快讯

美股大型科技股盘前多数下跌,谷歌跌超7%

36氪获悉,美股大型科技股盘前多数下跌,截至发稿,谷歌跌超7%,亚马逊、苹果跌超1%,特斯拉跌0.92%,微软跌0.36%,Meta跌0.35%,奈飞跌0.14%;英伟达涨近1%。

4分钟前

热门中概股美股盘前多数走弱,拼多多跌超7%

36氪获悉,热门中概股美股盘前多数走弱,截至发稿,拼多多跌超7%,理想汽车、微博跌超3%,阿里巴巴、京东、百度、蔚来跌超2%,小鹏汽车、爱奇艺跌超1%;B站涨超1%。

4分钟前

君实生物:AWT020注射用无菌粉末临床试验申请获批

36氪获悉,君实生物公告,近日,公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,AWT020注射用无菌粉末(项目代号“JS213”)的临床试验申请获得批准。JS213是PD-1和白细胞介素-2双功能性抗体融合蛋白,主要用于晚期恶性肿瘤的治疗。

4分钟前

渣打集团任命Maria Ramos接替韦浩思担任集团主席

2月4日,渣打集团董事会宣布,鉴于韦浩思(José Viñals)已接近他服务满9年的任期,已任命Maria Ramos(65岁)接替韦浩思担任集团主席。待取得监管批准后,Maria将于公司在2025年5月8日举行的2025年股东周年大会后履新,而韦浩思届时将自董事会退任。(界面)

4分钟前

三六零:公司暂未向DeepSeek提供任何服务

36氪获悉,三六零公告,公司股票于2025年1月24日、1月27日、2月5日连续三个交易日内收盘价格涨幅偏离值累计超过20%,属于股票交易异常波动情形。经自查,公司注意到相关平台将公司股票纳入DeepSeek概念股。公司就相关事项澄清说明如下:在DeepSeek基于MIT开源协议的生态环境下,公司旗下的部分产品进行了DeepSeek的接入与本地化部署;公司暂未向DeepSeek提供任何服务。除上述事项外,公司未发现其他可能对公司股票交易价格产生较大影响的、需要公司澄清或回应的媒体报道或市场传闻

4分钟前

本页详细列出关于前列康的品牌信息,含品牌所属公司介绍,前列康所处行业的品牌地位及优势。
咨询